Thrombosis
Conference Coverage
Novel celery seed–derived drug may improve stroke outcomes
Patients treated with butylphthalide had fewer severe neurologic symptoms and better function 90 days after the stroke, compared with those...
From the Journals
Cardiac issues twice as likely with COVID plus high troponin
Hospitalized COVID-19 patients with high troponin levels were twice as likely to have cardiac abnormalities due to diverse causes in a large U.K....
Conference Coverage
STROKE AF at 3 years: High AFib rate after atherosclerotic stroke
Continuous monitoring to detect AFib should be considered in a larger population of stroke patients rather than just those with cryptogenic stroke...
Commentary
Universal testing for Lp(a): What are we waiting for?
A resurgent interest in molecular pathophysiology this past decade has clarified Lp(a)’s unique contribution to atherothrombotic disease and...
From the Journals
After PCI, 1-month beats 12-month DAPT in high-risk patients
When dual was replaced by single antiplatelet therapy 1 month after PCI in Japanese patients, bleeding risk declined.
Latest News
Warfarin best for thrombotic antiphospholipid syndrome?
A vitamin K antagonist such as warfarin, rather than a direct oral anticoagulant, appears to be a better treatment for patients with thrombotic...
From the Journals
Statins tied to lower ICH risk regardless of bleed location
A large new case-control study has shown a reduced risk of both lobar and nonlobar intracerebral hemorrhage with statin use, providing reassurance...
Conference Coverage
No benefit of rivaroxaban in COVID outpatients: PREVENT-HD
PREVENT-HD joins a long list of smaller trials also showing no benefit of anticoagulation in nonhospitalized COVID-19 patients.
Conference Coverage
EHR-based thromboembolism risk tool boosted prophylaxis
A thromboembolism risk calculator in a hospital’s EHR led to a significant rise in appropriate thromboprophylaxis and a drop in thromboembolic...
Conference Coverage
Combo thrombolytic approach fails to reduce ICH in stroke
Although there were promising signs of a potential reduced bleeding risk in intracranial hemorrhage, the DUMAS study showed no benefit on the...
From the Journals
Best anticoagulant for minimizing bleeding risk identified
“Apixaban stood out as having lower risk of gastrointestinal bleeding.”